Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
1 hedge funds and large institutions have $0 invested in Acceleron Pharma in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 325 closing their positions.
100% less funds holding
Funds holding: 330 → 1 (-329)
100% less funds holding in top 10
Funds holding in top 10: 13 → 0 (-13)
100% less capital invested
Capital invested by funds: $9.13B → $0 (-$9.13B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 325
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$923M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$848M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$688M |
| 4 |
BlackRock
New York
|
-$684M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$373M |
XLRN Hedge Fund Activity: Q4 2021 in Review
1 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2021, worth a combined $0 — down 100% from $9.13B a quarter earlier.
Sellers outnumbered buyers: 325 funds closed out of XLRN and 0 opened new positions — a net loss of 325 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $923M sold.
- 1 institutional investor held Acceleron Pharma (XLRN) as of Q4 2021, down from 330 in Q3 2021.
- Funds reported $0 of Acceleron Pharma stock for Q4 2021, down 100% quarter-over-quarter.
- 0 funds opened new Acceleron Pharma positions in Q4 2021 and 325 closed out, a net change of -325 holders.
- The largest Acceleron Pharma seller in Q4 2021 was T. Rowe Price Associates, an estimated $923M sold.
Based on aggregated 13F filings for Q4 2021.